Table 5 CCRT outcomes and antimicrobial adverse events by the fourth day of CCRT activation by group
Cases N = 157 | Control N = 158 | Total N = 315 | p-value | |
|---|---|---|---|---|
Outcome | ||||
Stay at floor | 77 (49.0%) | 94 (59.5%) | 171 (54.3%) | 0.063 |
Admission to intensive care unit | 69 (43.9%) | 45 (28.5%) | 114 (36.2%) | 0.004 |
Death | 7 (4.5%) | 2 (1.3%) | 9 (2.9%) | 0.104 |
Discharge home | 0 (0.0%) | 2 (1.3%) | 2 (0.6%) | 0.498 |
Others | 0 (0.0%) | 2 (1.3%) | 2 (0.6%) | 0.498 |
Antimicrobial adverse events | ||||
None | 107 (68.2%) | 115 (72.8%) | 222 (70.5%) | 0.270 |
One | 36 (22.9%) | 36 (22.8%) | 72 (22.9%) | |
Two or more | 14 (8.9%) | 7 (4.4%) | 21 (6.7%) | |
Types of antimicrobial adverse events | ||||
Renal | 21 (13.4%) | 18 (11.4%) | 39 (12.4%) | 0.593 |
Hematologic | 17 (10.8%) | 19 (12.0%) | 36 (11.4%) | 0.738 |
Gastrointestinal | 17 (10.8%) | 7 (4.4%) | 24 (7.6%) | 0.032 |
Hepatic | 8 (5.1%) | 6 (3.8%) | 14 (4.4%) | 0.576 |
Skin | 3 (1.9%) | 1 (0.6%) | 4 (1.3%) | 0.371 |
Anaphylaxis | 0 (0.0%) | 1 (0.6%) | 1 (0.3%) | > 0.99 |